While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

Friday, Aurora Therapeutics debuted with $16 million in seed capital from Menlo Ventures. Its goal: To develop the industry’s ...

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P.

In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to BioSpace tallies. BioSpace ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...